IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company dedicated to the discovery, development, and commercialization of transformative therapies for cancer. The company's mission is to alter the course of disease and improve clinical outcomes for patients by integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers. IDEAYA Biosciences is headquartered in South San Francisco, California.

The company's pipeline is primarily focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Key product candidates include darovasertib (IDE196), a PKC inhibitor for genetically-defined cancers such as uveal melanoma; IDE397, a MAT2A inhibitor targeting tumors with MTAP gene deletion; IDE161, a PARG inhibitor for tumors with homologous recombination deficiency (HRD); and IDE849, a DLL3 TOP1 ADC for small cell lung cancer and neuroendocrine cancer. Other programs include IDE574, a KAT6/7 dual inhibitor, and IDE275 (GSK959), a Werner Helicase inhibitor developed in collaboration with GlaxoSmithKline.

In recent news, the U.S. Food and Drug Administration (FDA) has agreed to review IDEAYA's New Drug Application (NDA) for darovasertib in combination with crizotinib for first-line HLA-A2-negative metastatic uveal melanoma under the Real-Time Oncology Review (RTOR) program, following positive Phase 2/3 OptimUM-02 trial results. Full data from this trial are expected to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2026. Yujiro S. Hata serves as the President, Chief Executive Officer, and Founder, with Dr. Theodora Ross appointed as Chief Development Officer in February 2026. The company maintains a strong market position as a clinical-stage entity with a deep pipeline and a cash runway anticipated to fund operations into 2029 or 2030.